

# Global Generic Drugs Market Analysis and Forecast 2024-2030

<https://marketpublishers.com/r/G693D1CEF368EN.html>

Date: April 2024

Pages: 215

Price: US\$ 4,950.00 (Single User License)

ID: G693D1CEF368EN

## Abstracts

### Summary

A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.

According to APO Research, The global Generic Drugs market is projected to grow from US\$ million in 2024 to US\$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Generic Drugs is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Generic Drugs is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Generic Drugs is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Generic Drugs is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through

2030.

The major global companies of Generic Drugs include Teva, Novartis - Sandoz, Mylan, Sun Pharmaceutical, Aspen, Fresenius Kabi, Pfizer (Hospira), Sanofi and Aurobindo, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

### Report Includes

This report presents an overview of global market for Generic Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Generic Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Generic Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Generic Drugs revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Generic Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Generic Drugs revenue, projected growth trends, production technology, application and end-user industry.

### Generic Drugs segment by Company

Teva

Novartis - Sandoz

Mylan

Sun Pharmaceutical

Aspen

Fresenius Kabi

Pfizer (Hospira)

Sanofi

Aurobindo

Lupin

Dr. Reddy's

Apotex

Cipla

ENDO (Par Pharmaceutical)

Stada Arzneimittel

Krka Group

Nichi-Iko Pharmaceutical

Valeant

Zydus Cadila

Hikma

Pharmaniaga Berhad

Hovid Berhad

Duopharma Biotech

Kotra Pharma

HOE Pharmaceutical

Y.S.P. Industries

### Generic Drugs segment by Type

Prescription

Non-Prescription Drugs

### Generic Drugs segment by Application

Hospital

Clinic

Others

### Generic Drugs segment by Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

#### Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

#### Latin America

Mexico

Brazil

Argentina

#### Middle East & Africa

Turkey

Saudi Arabia

## UAE

### Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

### Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Generic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

## Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Generic Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Generic Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find

the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Generic Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.



## Contents

### **1 MARKET OVERVIEW**

- 1.1 Product Definition
- 1.2 Generic Drugs Market by Type
  - 1.2.1 Global Generic Drugs Market Size by Type, 2019 VS 2023 VS 2030
  - 1.2.2 Prescription
  - 1.2.3 Non-Prescription Drugs
- 1.3 Generic Drugs Market by Application
  - 1.3.1 Global Generic Drugs Market Size by Application, 2019 VS 2023 VS 2030
  - 1.3.2 Hospital
  - 1.3.3 Clinic
  - 1.3.4 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives

### **2 GENERIC DRUGS MARKET DYNAMICS**

- 2.1 Generic Drugs Industry Trends
- 2.2 Generic Drugs Industry Drivers
- 2.3 Generic Drugs Industry Opportunities and Challenges
- 2.4 Generic Drugs Industry Restraints

### **3 GLOBAL GROWTH PERSPECTIVE**

- 3.1 Global Generic Drugs Market Perspective (2019-2030)
- 3.2 Global Generic Drugs Growth Trends by Region
  - 3.2.1 Global Generic Drugs Market Size by Region: 2019 VS 2023 VS 2030
  - 3.2.2 Global Generic Drugs Market Size by Region (2019-2024)
  - 3.2.3 Global Generic Drugs Market Size by Region (2025-2030)

### **4 COMPETITIVE LANDSCAPE BY PLAYERS**

- 4.1 Global Generic Drugs Revenue by Players
  - 4.1.1 Global Generic Drugs Revenue by Players (2019-2024)
  - 4.1.2 Global Generic Drugs Revenue Market Share by Players (2019-2024)
  - 4.1.3 Global Generic Drugs Players Revenue Share Top 10 and Top 5 in 2023
- 4.2 Global Generic Drugs Key Players Ranking, 2022 VS 2023 VS 2024

- 4.3 Global Generic Drugs Key Players Headquarters & Area Served
- 4.4 Global Generic Drugs Players, Product Type & Application
- 4.5 Global Generic Drugs Players Commercialization Time
- 4.6 Market Competitive Analysis
  - 4.6.1 Global Generic Drugs Market CR5 and HHI
  - 4.6.2 Global Top 5 and 10 Generic Drugs Players Market Share by Revenue in 2023
  - 4.6.3 2023 Generic Drugs Tier 1, Tier 2, and Tier

## **5 GENERIC DRUGS MARKET SIZE BY TYPE**

- 5.1 Global Generic Drugs Revenue by Type (2019 VS 2023 VS 2030)
- 5.2 Global Generic Drugs Revenue by Type (2019-2030)
- 5.3 Global Generic Drugs Revenue Market Share by Type (2019-2030)

## **6 GENERIC DRUGS MARKET SIZE BY APPLICATION**

- 6.1 Global Generic Drugs Revenue by Application (2019 VS 2023 VS 2030)
- 6.2 Global Generic Drugs Revenue by Application (2019-2030)
- 6.3 Global Generic Drugs Revenue Market Share by Application (2019-2030)

## **7 COMPANY PROFILES**

- 7.1 Teva
  - 7.1.1 Teva Company Information
  - 7.1.2 Teva Business Overview
  - 7.1.3 Teva Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.1.4 Teva Generic Drugs Product Portfolio
  - 7.1.5 Teva Recent Developments
- 7.2 Novartis - Sandoz
  - 7.2.1 Novartis - Sandoz Company Information
  - 7.2.2 Novartis - Sandoz Business Overview
  - 7.2.3 Novartis - Sandoz Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.2.4 Novartis - Sandoz Generic Drugs Product Portfolio
  - 7.2.5 Novartis - Sandoz Recent Developments
- 7.3 Mylan
  - 7.3.1 Mylan Company Information
  - 7.3.2 Mylan Business Overview
  - 7.3.3 Mylan Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.3.4 Mylan Generic Drugs Product Portfolio

- 7.3.5 Mylan Recent Developments
- 7.4 Sun Pharmaceutical
  - 7.4.1 Sun Pharmaceutical Company Information
  - 7.4.2 Sun Pharmaceutical Business Overview
  - 7.4.3 Sun Pharmaceutical Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.4.4 Sun Pharmaceutical Generic Drugs Product Portfolio
  - 7.4.5 Sun Pharmaceutical Recent Developments
- 7.5 Aspen
  - 7.5.1 Aspen Company Information
  - 7.5.2 Aspen Business Overview
  - 7.5.3 Aspen Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.5.4 Aspen Generic Drugs Product Portfolio
  - 7.5.5 Aspen Recent Developments
- 7.6 Fresenius Kabi
  - 7.6.1 Fresenius Kabi Company Information
  - 7.6.2 Fresenius Kabi Business Overview
  - 7.6.3 Fresenius Kabi Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.6.4 Fresenius Kabi Generic Drugs Product Portfolio
  - 7.6.5 Fresenius Kabi Recent Developments
- 7.7 Pfizer (Hospira)
  - 7.7.1 Pfizer (Hospira) Company Information
  - 7.7.2 Pfizer (Hospira) Business Overview
  - 7.7.3 Pfizer (Hospira) Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.7.4 Pfizer (Hospira) Generic Drugs Product Portfolio
  - 7.7.5 Pfizer (Hospira) Recent Developments
- 7.8 Sanofi
  - 7.8.1 Sanofi Company Information
  - 7.8.2 Sanofi Business Overview
  - 7.8.3 Sanofi Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.8.4 Sanofi Generic Drugs Product Portfolio
  - 7.8.5 Sanofi Recent Developments
- 7.9 Aurobindo
  - 7.9.1 Aurobindo Company Information
  - 7.9.2 Aurobindo Business Overview
  - 7.9.3 Aurobindo Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.9.4 Aurobindo Generic Drugs Product Portfolio
  - 7.9.5 Aurobindo Recent Developments
- 7.10 Lupin
  - 7.10.1 Lupin Company Information

- 7.10.2 Lupin Business Overview
- 7.10.3 Lupin Generic Drugs Revenue and Gross Margin (2019-2024)
- 7.10.4 Lupin Generic Drugs Product Portfolio
- 7.10.5 Lupin Recent Developments
- 7.11 Dr. Reddy's
  - 7.11.1 Dr. Reddy's Company Information
  - 7.11.2 Dr. Reddy's Business Overview
  - 7.11.3 Dr. Reddy's Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.11.4 Dr. Reddy's Generic Drugs Product Portfolio
  - 7.11.5 Dr. Reddy's Recent Developments
- 7.12 Apotex
  - 7.12.1 Apotex Company Information
  - 7.12.2 Apotex Business Overview
  - 7.12.3 Apotex Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.12.4 Apotex Generic Drugs Product Portfolio
  - 7.12.5 Apotex Recent Developments
- 7.13 Cipla
  - 7.13.1 Cipla Company Information
  - 7.13.2 Cipla Business Overview
  - 7.13.3 Cipla Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.13.4 Cipla Generic Drugs Product Portfolio
  - 7.13.5 Cipla Recent Developments
- 7.14 ENDO (Par Pharmaceutical)
  - 7.14.1 ENDO (Par Pharmaceutical) Company Information
  - 7.14.2 ENDO (Par Pharmaceutical) Business Overview
  - 7.14.3 ENDO (Par Pharmaceutical) Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.14.4 ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio
  - 7.14.5 ENDO (Par Pharmaceutical) Recent Developments
- 7.15 Stada Arzneimittel
  - 7.15.1 Stada Arzneimittel Company Information
  - 7.15.2 Stada Arzneimittel Business Overview
  - 7.15.3 Stada Arzneimittel Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.15.4 Stada Arzneimittel Generic Drugs Product Portfolio
  - 7.15.5 Stada Arzneimittel Recent Developments
- 7.16 Krka Group
  - 7.16.1 Krka Group Company Information
  - 7.16.2 Krka Group Business Overview
  - 7.16.3 Krka Group Generic Drugs Revenue and Gross Margin (2019-2024)

- 7.16.4 Krka Group Generic Drugs Product Portfolio
- 7.16.5 Krka Group Recent Developments
- 7.17 Nichi-Iko Pharmaceutical
  - 7.17.1 Nichi-Iko Pharmaceutical Company Information
  - 7.17.2 Nichi-Iko Pharmaceutical Business Overview
  - 7.17.3 Nichi-Iko Pharmaceutical Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.17.4 Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio
  - 7.17.5 Nichi-Iko Pharmaceutical Recent Developments
- 7.18 Valeant
  - 7.18.1 Valeant Company Information
  - 7.18.2 Valeant Business Overview
  - 7.18.3 Valeant Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.18.4 Valeant Generic Drugs Product Portfolio
  - 7.18.5 Valeant Recent Developments
- 7.19 Zydus Cadila
  - 7.19.1 Zydus Cadila Company Information
  - 7.19.2 Zydus Cadila Business Overview
  - 7.19.3 Zydus Cadila Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.19.4 Zydus Cadila Generic Drugs Product Portfolio
  - 7.19.5 Zydus Cadila Recent Developments
- 7.20 Hikma
  - 7.20.1 Hikma Company Information
  - 7.20.2 Hikma Business Overview
  - 7.20.3 Hikma Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.20.4 Hikma Generic Drugs Product Portfolio
  - 7.20.5 Hikma Recent Developments
- 7.21 Pharmaniaga Berhad
  - 7.21.1 Pharmaniaga Berhad Company Information
  - 7.21.2 Pharmaniaga Berhad Business Overview
  - 7.21.3 Pharmaniaga Berhad Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.21.4 Pharmaniaga Berhad Generic Drugs Product Portfolio
  - 7.21.5 Pharmaniaga Berhad Recent Developments
- 7.22 Hovid Berhad
  - 7.22.1 Hovid Berhad Company Information
  - 7.22.2 Hovid Berhad Business Overview
  - 7.22.3 Hovid Berhad Generic Drugs Revenue and Gross Margin (2019-2024)
  - 7.22.4 Hovid Berhad Generic Drugs Product Portfolio
  - 7.22.5 Hovid Berhad Recent Developments

## 7.23 Duopharma Biotech

7.23.1 Duopharma Biotech Company Information

7.23.2 Duopharma Biotech Business Overview

7.23.3 Duopharma Biotech Generic Drugs Revenue and Gross Margin (2019-2024)

7.23.4 Duopharma Biotech Generic Drugs Product Portfolio

7.23.5 Duopharma Biotech Recent Developments

## 7.24 Kotra Pharma

7.24.1 Kotra Pharma Company Information

7.24.2 Kotra Pharma Business Overview

7.24.3 Kotra Pharma Generic Drugs Revenue and Gross Margin (2019-2024)

7.24.4 Kotra Pharma Generic Drugs Product Portfolio

7.24.5 Kotra Pharma Recent Developments

## 7.25 HOE Pharmaceutical

7.25.1 HOE Pharmaceutical Company Information

7.25.2 HOE Pharmaceutical Business Overview

7.25.3 HOE Pharmaceutical Generic Drugs Revenue and Gross Margin (2019-2024)

7.25.4 HOE Pharmaceutical Generic Drugs Product Portfolio

7.25.5 HOE Pharmaceutical Recent Developments

## 7.26 Y.S.P. Industries

7.26.1 Y.S.P. Industries Company Information

7.26.2 Y.S.P. Industries Business Overview

7.26.3 Y.S.P. Industries Generic Drugs Revenue and Gross Margin (2019-2024)

7.26.4 Y.S.P. Industries Generic Drugs Product Portfolio

7.26.5 Y.S.P. Industries Recent Developments

## **8 NORTH AMERICA**

8.1 North America Generic Drugs Revenue (2019-2030)

8.2 North America Generic Drugs Revenue by Type (2019-2030)

8.2.1 North America Generic Drugs Revenue by Type (2019-2024)

8.2.2 North America Generic Drugs Revenue by Type (2025-2030)

8.3 North America Generic Drugs Revenue Share by Type (2019-2030)

8.4 North America Generic Drugs Revenue by Application (2019-2030)

8.4.1 North America Generic Drugs Revenue by Application (2019-2024)

8.4.2 North America Generic Drugs Revenue by Application (2025-2030)

8.5 North America Generic Drugs Revenue Share by Application (2019-2030)

8.6 North America Generic Drugs Revenue by Country

8.6.1 North America Generic Drugs Revenue by Country (2019 VS 2023 VS 2030)

8.6.2 North America Generic Drugs Revenue by Country (2019-2024)



### 8.6.3 North America Generic Drugs Revenue by Country (2025-2030)

#### 8.6.4 U.S.

#### 8.6.5 Canada

## 9 EUROPE

### 9.1 Europe Generic Drugs Revenue (2019-2030)

### 9.2 Europe Generic Drugs Revenue by Type (2019-2030)

#### 9.2.1 Europe Generic Drugs Revenue by Type (2019-2024)

#### 9.2.2 Europe Generic Drugs Revenue by Type (2025-2030)

### 9.3 Europe Generic Drugs Revenue Share by Type (2019-2030)

### 9.4 Europe Generic Drugs Revenue by Application (2019-2030)

#### 9.4.1 Europe Generic Drugs Revenue by Application (2019-2024)

#### 9.4.2 Europe Generic Drugs Revenue by Application (2025-2030)

### 9.5 Europe Generic Drugs Revenue Share by Application (2019-2030)

### 9.6 Europe Generic Drugs Revenue by Country

#### 9.6.1 Europe Generic Drugs Revenue by Country (2019 VS 2023 VS 2030)

#### 9.6.2 Europe Generic Drugs Revenue by Country (2019-2024)

#### 9.6.3 Europe Generic Drugs Revenue by Country (2025-2030)

#### 9.6.4 Germany

#### 9.6.5 France

#### 9.6.6 U.K.

#### 9.6.7 Italy

#### 9.6.8 Russia

## 10 CHINA

### 10.1 China Generic Drugs Revenue (2019-2030)

### 10.2 China Generic Drugs Revenue by Type (2019-2030)

#### 10.2.1 China Generic Drugs Revenue by Type (2019-2024)

#### 10.2.2 China Generic Drugs Revenue by Type (2025-2030)

### 10.3 China Generic Drugs Revenue Share by Type (2019-2030)

### 10.4 China Generic Drugs Revenue by Application (2019-2030)

#### 10.4.1 China Generic Drugs Revenue by Application (2019-2024)

#### 10.4.2 China Generic Drugs Revenue by Application (2025-2030)

### 10.5 China Generic Drugs Revenue Share by Application (2019-2030)

## 11 ASIA (EXCLUDING CHINA)

- 11.1 Asia Generic Drugs Revenue (2019-2030)
- 11.2 Asia Generic Drugs Revenue by Type (2019-2030)
  - 11.2.1 Asia Generic Drugs Revenue by Type (2019-2024)
  - 11.2.2 Asia Generic Drugs Revenue by Type (2025-2030)
- 11.3 Asia Generic Drugs Revenue Share by Type (2019-2030)
- 11.4 Asia Generic Drugs Revenue by Application (2019-2030)
  - 11.4.1 Asia Generic Drugs Revenue by Application (2019-2024)
  - 11.4.2 Asia Generic Drugs Revenue by Application (2025-2030)
- 11.5 Asia Generic Drugs Revenue Share by Application (2019-2030)
- 11.6 Asia Generic Drugs Revenue by Country
  - 11.6.1 Asia Generic Drugs Revenue by Country (2019 VS 2023 VS 2030)
  - 11.6.2 Asia Generic Drugs Revenue by Country (2019-2024)
  - 11.6.3 Asia Generic Drugs Revenue by Country (2025-2030)
  - 11.6.4 Japan
  - 11.6.5 South Korea
  - 11.6.6 India
  - 11.6.7 Australia
  - 11.6.8 China Taiwan
  - 11.6.9 Southeast Asia

## **12 MIDDLE EAST, AFRICA, LATIN AMERICA**

- 12.1 MEALA Generic Drugs Revenue (2019-2030)
- 12.2 MEALA Generic Drugs Revenue by Type (2019-2030)
  - 12.2.1 MEALA Generic Drugs Revenue by Type (2019-2024)
  - 12.2.2 MEALA Generic Drugs Revenue by Type (2025-2030)
- 12.3 MEALA Generic Drugs Revenue Share by Type (2019-2030)
- 12.4 MEALA Generic Drugs Revenue by Application (2019-2030)
  - 12.4.1 MEALA Generic Drugs Revenue by Application (2019-2024)
  - 12.4.2 MEALA Generic Drugs Revenue by Application (2025-2030)
- 12.5 MEALA Generic Drugs Revenue Share by Application (2019-2030)
- 12.6 MEALA Generic Drugs Revenue by Country
  - 12.6.1 MEALA Generic Drugs Revenue by Country (2019 VS 2023 VS 2030)
  - 12.6.2 MEALA Generic Drugs Revenue by Country (2019-2024)
  - 12.6.3 MEALA Generic Drugs Revenue by Country (2025-2030)
  - 12.6.4 Mexico
  - 12.6.5 Brazil
  - 12.6.6 Israel
  - 12.6.7 Argentina



12.6.8 Colombia

12.6.9 Turkey

12.6.10 Saudi Arabia

12.6.11 UAE

## **13 CONCLUDING INSIGHTS**

## **14 APPENDIX**

14.1 Reasons for Doing This Study

14.2 Research Methodology

14.3 Research Process

14.4 Authors List of This Report

14.5 Data Source

14.5.1 Secondary Sources

14.5.2 Primary Sources

14.6 Disclaimer

## List Of Tables

### LIST OF TABLES

- Table 1. Global Generic Drugs Market Size Growth Rate by Type (US\$ Million), 2019 VS 2023 VS 2030
- Table 1. Prescription Major Manufacturers
- Table 2. Non-Prescription Drugs Major Manufacturers
- Table 3. Global Generic Drugs Market Size Growth Rate by Application (US\$ Million), 2019 VS 2023 VS 2030
- Table 4. Hospital Major Manufacturers
- Table 5. Clinic Major Manufacturers
- Table 6. Others Major Manufacturers
- Table 7. Generic Drugs Industry Trends
- Table 8. Generic Drugs Industry Drivers
- Table 9. Generic Drugs Industry Opportunities and Challenges
- Table 10. Generic Drugs Industry Restraints
- Table 11. Global Generic Drugs Market Size Growth Rate (CAGR) by Region (US\$ Million): 2019 VS 2023 VS 2030
- Table 12. Global Generic Drugs Market Size by Region (2019-2024) & (US\$ Million)
- Table 13. Global Generic Drugs Market Share by Region (2019-2024)
- Table 14. Global Generic Drugs Market Size by Region (2025-2030) & (US\$ Million)
- Table 15. Global Generic Drugs Market Share by Region (2025-2030)
- Table 16. Global Generic Drugs Revenue by Players (US\$ Million) & (2019-2024)
- Table 17. Global Generic Drugs Revenue Market Share by Players (2019-2024)
- Table 18. Global Generic Drugs Key Players Ranking, 2022 VS 2023 VS 2024
- Table 19. Global Generic Drugs Key Players Headquarters & Area Served
- Table 20. Global Generic Drugs Players, Product Type & Application
- Table 21. Global Generic Drugs Players Commercialization Time
- Table 22. Global Players Market Concentration Ratio (CR5 and HHI)
- Table 23. Global Generic Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
- Table 24. Global Generic Drugs Revenue by Type 2019 VS 2023 VS 2030 (US\$ Million)
- Table 25. Global Generic Drugs Revenue by Type (2019-2024) & (US\$ Million)
- Table 26. Global Generic Drugs Revenue by Type (2025-2030) & (US\$ Million)
- Table 27. Global Generic Drugs Revenue Market Share by Type (2019-2024) & (US\$ Million)
- Table 28. Global Generic Drugs Revenue Market Share by Type (2025-2030) & (US\$ Million)

Table 29. Global Generic Drugs Revenue by Application 2019 VS 2023 VS 2030 (US\$ Million)

Table 30. Global Generic Drugs Revenue by Application (2019-2024) & (US\$ Million)

Table 31. Global Generic Drugs Revenue by Application (2025-2030) & (US\$ Million)

Table 32. Global Generic Drugs Revenue Market Share by Application (2019-2024) & (US\$ Million)

Table 33. Global Generic Drugs Revenue Market Share by Application (2025-2030) & (US\$ Million)

Table 34. Teva Company Information

Table 35. Teva Business Overview

Table 36. Teva Generic Drugs Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 37. Teva Generic Drugs Product Portfolio

Table 38. Teva Recent Development

Table 39. Novartis - Sandoz Company Information

Table 40. Novartis - Sandoz Business Overview

Table 41. Novartis - Sandoz Generic Drugs Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 42. Novartis - Sandoz Generic Drugs Product Portfolio

Table 43. Novartis - Sandoz Recent Development

Table 44. Mylan Company Information

Table 45. Mylan Business Overview

Table 46. Mylan Generic Drugs Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 47. Mylan Generic Drugs Product Portfolio

Table 48. Mylan Recent Development

Table 49. Sun Pharmaceutical Company Information

Table 50. Sun Pharmaceutical Business Overview

Table 51. Sun Pharmaceutical Generic Drugs Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 52. Sun Pharmaceutical Generic Drugs Product Portfolio

Table 53. Sun Pharmaceutical Recent Development

Table 54. Aspen Company Information

Table 55. Aspen Business Overview

Table 56. Aspen Generic Drugs Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 57. Aspen Generic Drugs Product Portfolio

Table 58. Aspen Recent Development

Table 59. Fresenius Kabi Company Information

Table 60. Fresenius Kabi Business Overview

Table 61. Fresenius Kabi Generic Drugs Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 62. Fresenius Kabi Generic Drugs Product Portfolio

Table 63. Fresenius Kabi Recent Development

Table 64. Pfizer (Hospira) Company Information

Table 65. Pfizer (Hospira) Business Overview

Table 66. Pfizer (Hospira) Generic Drugs Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 67. Pfizer (Hospira) Generic Drugs Product Portfolio

Table 68. Pfizer (Hospira) Recent Development

Table 69. Sanofi Company Information

Table 70. Sanofi Business Overview

Table 71. Sanofi Generic Drugs Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 72. Sanofi Generic Drugs Product Portfolio

Table 73. Sanofi Recent Development

Table 74. Aurobindo Company Information

Table 75. Aurobindo Business Overview

Table 76. Aurobindo Generic Drugs Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 77. Aurobindo Generic Drugs Product Portfolio

Table 78. Aurobindo Recent Development

Table 79. Lupin Company Information

Table 80. Lupin Business Overview

Table 81. Lupin Generic Drugs Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 82. Lupin Generic Drugs Product Portfolio

Table 83. Lupin Recent Development

Table 84. Dr. Reddy's Company Information

Table 85. Dr. Reddy's Business Overview

Table 86. Dr. Reddy's Generic Drugs Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 87. Dr. Reddy's Generic Drugs Product Portfolio

Table 88. Dr. Reddy's Recent Development

Table 89. Apotex Company Information

Table 90. Apotex Business Overview

Table 91. Apotex Generic Drugs Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 92. Apotex Generic Drugs Product Portfolio

Table 93. Apotex Recent Development

- Table 94. Cipla Company Information
- Table 95. Cipla Business Overview
- Table 96. Cipla Generic Drugs Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)
- Table 97. Cipla Generic Drugs Product Portfolio
- Table 98. Cipla Recent Development
- Table 99. ENDO (Par Pharmaceutical) Company Information
- Table 100. ENDO (Par Pharmaceutical) Business Overview
- Table 101. ENDO (Par Pharmaceutical) Generic Drugs Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)
- Table 102. ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio
- Table 103. ENDO (Par Pharmaceutical) Recent Development
- Table 104. Stada Arzneimittel Company Information
- Table 105. Stada Arzneimittel Business Overview
- Table 106. Stada Arzneimittel Generic Drugs Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)
- Table 107. Stada Arzneimittel Generic Drugs Product Portfolio
- Table 108. Stada Arzneimittel Recent Development
- Table 109. Krka Group Company Information
- Table 110. Krka Group Business Overview
- Table 111. Krka Group Generic Drugs Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)
- Table 112. Krka Group Generic Drugs Product Portfolio
- Table 113. Krka Group Recent Development
- Table 114. Nichi-Iko Pharmaceutical Company Information
- Table 115. Nichi-Iko Pharmaceutical Business Overview
- Table 116. Nichi-Iko Pharmaceutical Generic Drugs Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)
- Table 117. Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio
- Table 118. Nichi-Iko Pharmaceutical Recent Development
- Table 119. Valeant Company Information
- Table 120. Valeant Business Overview
- Table 121. Valeant Generic Drugs Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)
- Table 122. Valeant Generic Drugs Product Portfolio
- Table 123. Valeant Recent Development
- Table 124. Zydus Cadila Company Information
- Table 125. Zydus Cadila Business Overview
- Table 126. Zydus Cadila Generic Drugs Sales (K MT), Revenue (US\$ Million), Price

(USD/MT) and Gross Margin (2019-2024)

Table 127. Zydus Cadila Generic Drugs Product Portfolio

Table 128. Zydus Cadila Recent Development

Table 129. Hikma Company Information

Table 130. Hikma Business Overview

Table 131. Hikma Generic Drugs Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 132. Hikma Generic Drugs Product Portfolio

Table 133. Hikma Recent Development

Table 134. Pharmaniaga Berhad Company Information

Table 135. Pharmaniaga Berhad Business Overview

Table 136. Pharmaniaga Berhad Generic Drugs Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 137. Pharmaniaga Berhad Generic Drugs Product Portfolio

Table 138. Pharmaniaga Berhad Recent Development

Table 139. Hovid Berhad Company Information

Table 140. Hovid Berhad Business Overview

Table 141. Hovid Berhad Generic Drugs Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 142. Hovid Berhad Generic Drugs Product Portfolio

Table 143. Hovid Berhad Recent Development

Table 144. Duopharma Biotech Company Information

Table 145. Duopharma Biotech Business Overview

Table 146. Duopharma Biotech Generic Drugs Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 147. Duopharma Biotech Generic Drugs Product Portfolio

Table 148. Duopharma Biotech Recent Development

Table 149. Kotra Pharma Company Information

Table 150. Kotra Pharma Business Overview

Table 151. Kotra Pharma Generic Drugs Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 152. Kotra Pharma Generic Drugs Product Portfolio

Table 153. Kotra Pharma Recent Development

Table 154. HOE Pharmaceutical Company Information

Table 155. HOE Pharmaceutical Business Overview

Table 156. HOE Pharmaceutical Generic Drugs Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 157. HOE Pharmaceutical Generic Drugs Product Portfolio

Table 158. HOE Pharmaceutical Recent Development



- Table 159. Y.S.P. Industries Company Information
- Table 160. Y.S.P. Industries Business Overview
- Table 161. Y.S.P. Industries Generic Drugs Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)
- Table 162. Y.S.P. Industries Generic Drugs Product Portfolio
- Table 163. Y.S.P. Industries Recent Development
- Table 164. North America Generic Drugs Revenue by Type (2019-2024) & (US\$ Million)
- Table 165. North America Generic Drugs Revenue by Application (2019-2024) & (US\$ Million)
- Table 166. North America Generic Drugs Revenue by Country (2019 VS 2023 VS 2030) & (US\$ Million)
- Table 167. North America Generic Drugs Revenue by Country (2019-2024) & (US\$ Million)
- Table 168. North America Generic Drugs Revenue by Country (2025-2030) & (US\$ Million)
- Table 169. Europe Generic Drugs Revenue by Type (2019-2024) & (US\$ Million)
- Table 170. Europe Generic Drugs Revenue by Application (2019-2024) & (US\$ Million)
- Table 171. Europe Generic Drugs Revenue by Country (2019 VS 2023 VS 2030) & (US\$ Million)
- Table 172. Europe Generic Drugs Revenue by Country (2019-2024) & (US\$ Million)
- Table 173. Europe Generic Drugs Revenue by Country (2025-2030) & (US\$ Million)
- Table 174. China Generic Drugs Revenue by Type (2019-2024) & (US\$ Million)
- Table 175. China Generic Drugs Revenue by Application (2019-2024) & (US\$ Million)
- Table 176. Asia Generic Drugs Revenue by Type (2019-2024) & (US\$ Million)
- Table 177. Asia Generic Drugs Revenue by Application (2019-2024) & (US\$ Million)
- Table 178. Asia Generic Drugs Revenue by Country (2019 VS 2023 VS 2030) & (US\$ Million)
- Table 179. Asia Generic Drugs Revenue by Country (2019-2024) & (US\$ Million)
- Table 180. Asia Generic Drugs Revenue by Country (2025-2030) & (US\$ Million)
- Table 181. MEALA Generic Drugs Revenue by Type (2019-2024) & (US\$ Million)
- Table 182. MEALA Generic Drugs Revenue by Application (2019-2024) & (US\$ Million)
- Table 183. MEALA Generic Drugs Revenue by Country (2019 VS 2023 VS 2030) & (US\$ Million)
- Table 184. MEALA Generic Drugs Revenue by Country (2019-2024) & (US\$ Million)
- Table 185. MEALA Generic Drugs Revenue by Country (2025-2030) & (US\$ Million)
- Table 186. Research Programs/Design for This Report
- Table 187. Authors List of This Report
- Table 188. Secondary Sources
- Table 189. Primary Sources





## List Of Figures

### LIST OF FIGURES

Figure 1. Generic Drugs Product Picture

Figure 2. Global Generic Drugs Market Size Growth Rate by Type (US\$ Million), 2019 VS 2023 VS 2030

Figure 3. Global Generic Drugs Market Size Share 2019 VS 2023 VS 2030

Figure 4. Prescription Picture

Figure 5. Non-Prescription Drugs Picture

Figure 6. Global Generic Drugs Market Size Growth Rate by Application (US\$ Million), 2019 VS 2023 VS 2030

Figure 7. Global Generic Drugs Market Size Share 2019 VS 2023 VS 2030

Figure 8. Hospital Picture

Figure 9. Clinic Picture

Figure 10. Others Picture

Figure 11. Global Generic Drugs Market Size (US\$ Million) & (2019-2030)

Figure 12. Global Generic Drugs Market Size, (US\$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Generic Drugs Market Share by Region: 2019 VS 2023 VS 2030

Figure 14. Global Generic Drugs Players Revenue Share Top 10 and Top 5 in 2023

Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 16. Global Generic Drugs Revenue by Type (2019 VS 2023 VS 2030) & (US\$ Million)

Figure 17. Global Generic Drugs Revenue Market Share 2019 VS 2023 VS 2030

Figure 18. Global Generic Drugs Revenue Market Share by Type (2019-2030)

Figure 19. Global Generic Drugs Revenue by Application (2019 VS 2023 VS 2030) & (US\$ Million)

Figure 20. Global Generic Drugs Revenue Market Share by Application (2019 VS 2023 VS 2030)

Figure 21. Global Generic Drugs Revenue Market Share by Application (2019-2030)

Figure 22. North America Generic Drugs Revenue YoY Growth (2019-2030) & (US\$ Million)

Figure 23. North America Generic Drugs Revenue by Type (2025-2030) & (US\$ Million)

Figure 24. North America Generic Drugs Revenue Share by Type (2019-2030)

Figure 25. North America Generic Drugs Revenue by Application (2025-2030) & (US\$ Million)

Figure 26. North America Generic Drugs Revenue Share by Application (2019-2030)

Figure 27. North America Generic Drugs Revenue Share by Country (2019-2030)

Figure 28. United States Generic Drugs Revenue YoY Growth (US\$ Million) &

(2019-2030)

Figure 29. Canada Generic Drugs Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 30. Europe Generic Drugs Revenue YoY Growth (2019-2030) & (US\$ Million)

Figure 31. Europe Generic Drugs Revenue by Type (2025-2030) & (US\$ Million)

Figure 32. Europe Generic Drugs Revenue Share by Type (2019-2030)

Figure 33. Europe Generic Drugs Revenue by Application (2025-2030) & (US\$ Million)

Figure 34. Europe Generic Drugs Revenue Share by Application (2019-2030)

Figure 35. Europe Generic Drugs Revenue Share by Country (2019-2030)

Figure 36. Germany Generic Drugs Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 37. France Generic Drugs Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 38. U.K. Generic Drugs Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 39. Italy Generic Drugs Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 40. Russia Generic Drugs Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 41. Nordic Countries Generic Drugs Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 42. China Generic Drugs Revenue YoY Growth (2019-2030) & (US\$ Million)

Figure 43. China Generic Drugs Revenue by Type (2025-2030) & (US\$ Million)

Figure 44. China Generic Drugs Revenue Share by Type (2019-2030)

Figure 45. China Generic Drugs Revenue by Application (2025-2030) & (US\$ Million)

Figure 46. China Generic Drugs Revenue Share by Application (2019-2030)

Figure 47. Asia Generic Drugs Revenue YoY Growth (2019-2030) & (US\$ Million)

Figure 48. Asia Generic Drugs Revenue by Type (2025-2030) & (US\$ Million)

Figure 49. Asia Generic Drugs Revenue Share by Type (2019-2030)

Figure 50. Asia Generic Drugs Revenue by Application (2025-2030) & (US\$ Million)

Figure 51. Asia Generic Drugs Revenue Share by Application (2019-2030)

Figure 52. Asia Generic Drugs Revenue Share by Country (2019-2030)

Figure 53. Japan Generic Drugs Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 54. South Korea Generic Drugs Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 55. India Generic Drugs Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 56. Australia Generic Drugs Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 57. China Taiwan Generic Drugs Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 58. Southeast Asia Generic Drugs Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 59. MEALA Generic Drugs Re

## I would like to order

Product name: Global Generic Drugs Market Analysis and Forecast 2024-2030

Product link: <https://marketpublishers.com/r/G693D1CEF368EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G693D1CEF368EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970